Logo image
Se connecter
2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)
Article de revue   Avec comité de lecture

2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)

E. Shinozaki, S. Laurent, C. Gravalos, M. Benavides, F. Longo Munoz, H. Mizuguchi, M. Wahba, M. Ychou, F. Ciardiello, S. Siena, …
European journal of cancer (1990), Vol.51, pp.S383-S384
09/2015

Indicateurs

1 Consultations de la notice

Détails

Logo image